Physician profile
Anne E Tague
NPI 1255521308
$5,643.45
in general payments reported to CMS, 2019-2025
22 companies · $828 in 2025
The $828 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $959 · 2022: $1,633 · 2023: $1,088 · 2024: $1,135 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,801 · Consulting Fee: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,801.13 |
| Consulting Fee | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,535.02 | 2021-2025 | Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $650.26 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $455.17 | 2021-2025 | Wainua, Fasenra, Farxiga |
| Cvrx, INC. | $436.74 | 2022-2025 | Barostim Neo System |
| Scpharmaceuticals INC. | $363.46 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $220.34 | 2021-2024 | |
| Abiomed | $213.79 | 2023 | Impella |
| Janssen Pharmaceuticals, INC | $195.00 | 2021-2023 | Opsumit |
| United Therapeutics Corporation | $190.00 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $167.83 | 2021 | |
| Glaxosmithkline, LLC. | $155.98 | 2021-2025 | Nucala |
| Actelion Pharmaceuticals US, INC. | $154.39 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $150.30 | 2023-2024 | Inpefa |
| Impulse Dynamics (USA) INC. | $141.87 | 2024 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $131.37 | 2021-2023 | Camzyos |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $122.10 | 2023 | |
| Mylan Specialty L.P. | $118.00 | 2024 | Yupelri |
| Itamar Medical INC | $108.32 | 2022 | |
| Boston Scientific Corporation | $50.63 | 2021-2023 | Watchman Access System |
| Merck Sharp & Dohme LLC | $35.01 | 2021-2023 | Verquvo |
| Bridgebio Pharma, INC. | $24.52 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $23.35 | 2024 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Tague listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.